506 related articles for article (PubMed ID: 26364362)
1. [PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia].
Saußele T
Med Monatsschr Pharm; 2015 Jul; 38(7):250-7. PubMed ID: 26364362
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
Okere AN; Serra C
Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
[TBL] [Abstract][Full Text] [Related]
3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
4. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
5. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
Paton DM
Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
[TBL] [Abstract][Full Text] [Related]
6. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Ling H; Burns TL; Hilleman DE
Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
[TBL] [Abstract][Full Text] [Related]
7. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.
Cicero AF; Tartagni E; Ertek S
Expert Opin Drug Saf; 2014 Aug; 13(8):1023-30. PubMed ID: 24961142
[TBL] [Abstract][Full Text] [Related]
9. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
Shimada YJ; Cannon CP
Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287
[TBL] [Abstract][Full Text] [Related]
10. Promising new therapies for the treatment of hypercholesterolemia.
Valerio MG; Velayati A; Jain D; Aronow WS
Expert Opin Biol Ther; 2016; 16(5):609-18. PubMed ID: 26822080
[TBL] [Abstract][Full Text] [Related]
11. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
Filardi PP; Paolillo S; Trimarco B
G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
[TBL] [Abstract][Full Text] [Related]
12. [PCSK9 inhibitors: new treatment to lower cholesterol].
Gencer B; Rodondi N; Mach F
Rev Med Suisse; 2016 Mar; 12(508):440-2, 444. PubMed ID: 27089600
[TBL] [Abstract][Full Text] [Related]
13. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
Tavori H; Melone M; Rashid S
Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.
Betteridge DJ
Nat Rev Endocrinol; 2013 Feb; 9(2):76-8. PubMed ID: 23296165
[TBL] [Abstract][Full Text] [Related]
15. Evolocumab (AMG 145) for primary hypercholesterolemia.
Langslet G; Emery M; Wasserman SM
Expert Rev Cardiovasc Ther; 2015 May; 13(5):477-88. PubMed ID: 25824308
[TBL] [Abstract][Full Text] [Related]
16. Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention.
Page MM; Watts GF
Expert Opin Emerg Drugs; 2015 Jun; 20(2):299-312. PubMed ID: 25861882
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
18. Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia.
Devito F; Zito A; Ricci G; Carbonara R; Dentamaro I; Cortese F; Carbonara S; Ciccone MM
Pharmacol Res; 2015 Dec; 102():168-75. PubMed ID: 26455563
[TBL] [Abstract][Full Text] [Related]
19. Anti-PCSK9 therapies for the treatment of hypercholesterolemia.
Hooper AJ; Burnett JR
Expert Opin Biol Ther; 2013 Mar; 13(3):429-35. PubMed ID: 23240807
[TBL] [Abstract][Full Text] [Related]
20. PCSK9 inhibitors: an overview on a new promising lipid-lowering therapy.
Denegri A; Petrova-Slater I; Pasotti E; Rossi MG; Pedrazzini GB; Moccetti T; Moccetti M
J Cardiovasc Med (Hagerstown); 2016 Apr; 17(4):237-44. PubMed ID: 26855411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
